

For Immediate Release

Company Name: Shinsei Bank, Limited
Name of Representative: Hideyuki Kudo
President and CEO
(Code: 8303, TSE First Section)

Establishment of Bio-Venture Investment Funds and Completion of Primary Offering

Tokyo (Monday, February 25, 2019) --- Shinsei Bank Group established New Life Science I Investment Limited Partnership (hereinafter, "the Fund") to invest in and support the growth of venture companies in the drug discovery and digital health fields, and completed the primary offering for a total of 9.1 billion yen on February 7, 2019.

Major investors for the primary offering are Organization for Small & Medium Enterprises and Regional Innovation, JAPAN (Minato-ku, Tokyo; Chairman & CEO: Hiroshi Takada), The Dai-ichi Life Insurance Company Limited (Chiyoda-ku, Tokyo; President: Seiji Inagaki), Shinsei Bank, Limited, as well as institutional investors, business corporations, and school corporations. The Fund plans to continue to make additional offering in the future.

Along with the structural changes in the life science industry, the commercialization of research results from Japanese academia, which possesses the world's leading scientific and technological capabilities, is advancing. At the same time, the importance of pharmaceutical development by bio-ventures is increasing, while there are many bio-ventures that have not grown sufficiently due to the delayed development of venture ecosystems.

The Fund aims to contribute to the creation of innovative pharmaceutical products originating in Japan by providing funds and hands-on support to these ventures. It will also provide growth funds and active support to ventures in the digital health field that utilize technology to realize advanced medical care and contribute to solving social problems such as soaring medical costs and declining medical services in depopulated areas.

The operations of the Fund are conducted by Shinsei Capital Partners, Ltd. (hereinafter, "SCP"). SCP was established by curving out the life sciences business of Shinsei Corporate Investment Limited through personal investments by Manabu Nakamura, who has led venture investments in the Shinsei Bank Group for about 14 years, as well as by Shinsei Bank's consolidated subsidiary Shinsei Corporate Investment Limited.

The SCP investment team is composed of Mr. Nakamura and former employees from pharmaceutical companies, and it is expected that they will utilize their long-standing investment experience and wide-ranging network and advanced knowledge to support the growth of venture companies in the life sciences field and secure sound investment returns.

Shinsei Bank Group has provided growth funds to middle and late-stage ventures as Pre-IPO investments, and has also actively established joint funds with external partners. In this project, we will carve out the investment business in the life science field that we have cultivated within Shinsei Bank Group and attract funds from outside investors based on independent decision-making, with the aim of further expanding investment in ventures in this field, including early-stage companies. In addition, we will continue to contribute to the development of new industrial sectors by providing risk money through proprietary investments and fund structuring.


■ Summary of the Fund

Name : New Life Science I Investment Limited Partnership
 Establishment : February 7, 2019
 Size : 9.1 billion yen at the time of the first close
 Investor : General partnership member (GP): New Life Science I LLP
 Limited partnership member (LP): Organization for Small & Medium Enterprises and Regional Innovation, Japan, The Dai-ichi Life Insurance Company, Limited, The Nanto Bank, Ltd., Yamasa Corporation, Shinsei Bank, Limited, and others
 Investment target : Venture companies in the field of drug discovery and digital health

■ Shinsei Capital Partners corporate profile

Name : Shinsei Capital Partners, Ltd. (<https://www.new-lifescience.com>)
 Representative : Manabu Nakamura(CEO)
 Establishment : April 18, 2018
 Capital : 9 million yen

【Fund's scheme】



End

Shinsei Bank is a leading diversified Japanese financial institution providing a various range of financial products and services to both institutional and individual customers. The Bank has a network of outlets throughout Japan and is committed in its pursuit of uncompromising levels of integrity and transparency in all of its activities in order to earn the trust of its customers, staff and shareholders. The Bank is committed to delivering long-term profit growth and increasing value for all its stakeholders. News and other information about Shinsei Bank is available at <https://www.shinseibank.com/corporate/en/index.html>